OncRef

Clinical Trial: NCT03502733

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:National Cancer Institute (NCI)
Information Provided By:National Cancer Institute (NCI)
Last Update Posted:2026-08-14

Study Overview

Brief Summary

This phase Ib trial studies the side effects and best dose of copanlisib and nivolumab and side effects of copanlisib given together with nivolumab and ipilimumab in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or lymphoma. Copanlisib stops tumors from growing by blocking proteins that are known to be important for tumor cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving copanlisib together with nivolumab or with nivolumab and ipilimumab may work better in treating patients with solid tumors or lymphoma.

Official Title

Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and Ipilimumab

Conditions

Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm

Intervention / Treatment

  • Procedure: Biopsy Procedure
  • Procedure: Biospecimen Collection
  • Procedure: Computed Tomography
  • Drug: Copanlisib
  • Procedure: Echocardiography Test
  • Biological: Ipilimumab
  • Procedure: Magnetic Resonance Imaging
  • Biological: Nivolumab

Other Study ID Numbers

  • NCI-2017-02249
  • NCI-2017-02249
  • NCI CC 18-C-0122
  • 10145
  • 10145
  • ZIABC011078

Start Date (Actual)

2018-08-14

Primary Completion Date (Estimated)

2027-08-01

Study Completion Date (Estimated)

2027-08-01

Enrollment (Estimated)

64

Study Type

Interventional

Phase

Phase 1